mRNA vaccines for infectious diseases—advances, challenges and opportunities

N Pardi, F Krammer - Nature Reviews Drug Discovery, 2024 - nature.com
The concept of mRNA-based vaccines emerged more than three decades ago.
Groundbreaking discoveries and technological advancements over the past 20 years have …

Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies

NI Mazur, MT Caballero, MC Nunes - The Lancet, 2024 - thelancet.com
The global burden of respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI)
in young children is high. The RSV prevention strategies approved in 2023 will be essential …

[HTML][HTML] Use of respiratory syncytial virus vaccines in adults aged≥ 60 years: updated recommendations of the Advisory Committee on Immunization Practices …

A Britton - MMWR. Morbidity and mortality weekly report, 2024 - cdc.gov
Respiratory syncytial virus (RSV) is a major cause of respiratory illness and hospitalization
in older adults during fall and winter in the United States. The 2023–2024 RSV season was …

Transforming vaccinology

R Rappuoli, G Alter, B Pulendran - Cell, 2024 - cell.com
The COVID-19 pandemic placed the field of vaccinology squarely at the center of global
consciousness, emphasizing the vital role of vaccines as transformative public health tools …

Rational formulation and industrial manufacturing of lipid-based complex injectables: Landmarks and trends

M Biscaia-Caleiras, NA Fonseca, AS Lourenço… - Journal of Controlled …, 2024 - Elsevier
Lipid-based complex injectables are renowned for their effectiveness in delivering drugs,
with many approved products. While significant strides have been made in formulating …

Advances in the design and delivery of RNA vaccines for infectious diseases

AG Lokras, TR Bobak, SS Baghel, F Sebastiani… - Advanced Drug Delivery …, 2024 - Elsevier
RNA medicines represent a paradigm shift in treatment and prevention of critical diseases of
global significance, eg, infectious diseases. The highly successful messenger RNA (mRNA) …

Humoral immunogenicity of mRNA-1345 RSV vaccine in older adults

J Goswami, AH Baqui, PA Doreski… - The Journal of …, 2024 - academic.oup.com
Background The mRNA-1345 vaccine demonstrated efficacy against respiratory syncytial
virus (RSV) disease with acceptable safety in adults aged≥ 60 years in the ConquerRSV …

Respiratory syncytial virus infections in adults: a narrative review

JG Wildenbeest, DM Lowe, JF Standing… - The Lancet Respiratory …, 2024 - thelancet.com
Respiratory syncytial virus (RSV), an RNA virus spread by droplet infection that affects all
ages, is increasingly recognised as an important pathogen in adults, especially among older …

Safety and immunogenicity of mRNA-1010, an investigational seasonal influenza vaccine, in healthy adults: final results from a phase 1/2 randomized trial

J Ananworanich, IT Lee, D Ensz… - The Journal of …, 2024 - academic.oup.com
Background Seasonal influenza remains a global public health concern. A messenger RNA
(mRNA)–based quadrivalent seasonal influenza vaccine, mRNA-1010, was investigated in …

Longitudinal humoral analysis in RSV-infected infants identifies pre-existing RSV strain-specific G and evolving cross-reactive F antibodies

N Nziza, W Jung, M Mendu, T Chen, B Julg, B Graham… - Immunity, 2024 - cell.com
Respiratory syncytial virus (RSV) is among the most common causes of lower respiratory
tract infection (LRTI) and hospitalization in infants. However, the mechanisms of immune …